IVCC this week attended Syngenta’s 2017 Good Growth Plan event in Brussels, Belgium.  Dr Nick Hamon, CEO of IVCC was interviewed about their partnership programme and spent time with Syngenta CEO Erik Fyrwald.  Earlier in the day, David Maguire, IVCC’s NgenIRS Director presented to over 200 invited guests providing an insight on how Syngenta’s malarial insecticide Actellic©CS300 is being used, with the support of IVCC and its funder UNITAID, to deliver next generation indoor residual spray programmes across sub-Saharan Africa.

Nick Hamon, CEO of IVCC said: “Field trial partners in Africa play an essential role in the testing of novel vector control products being developed and one of the most important elements of the field trial is the quality of the data generated, as this is the key to establishing the true nature of the products being tested.”

Since 2000, IVCC, in partnership with the London School of Hygiene & Tropical Medicine, has been working to strengthen the quality and reliability of data generated by African vector control field trial sites.  This work has included the development of Standard Operating Procedures (SOPs), the auditing of facilities, and follow-up Good Laboratory Practice (GLP) training workshops.

An important element of IVCC’s GLP rollout programme has also been its funding of infrastructure improvements including buildings and equipment at its collaborating trial sites.  This capacity building is establishing a network of facilities in Africa that can generate testing data on vector control products of the highest standard.

Professor Franklin Mosha, Test Facility Manager for the KCMUCo facility said: “Reaching this important milestone is a major achievement for IVCC and KCMUCo, and credit is due to all of the staff in Moshi who have implemented enormous changes in relation to their facilities, working practices and culture over a relatively short but intense period of time.”

Nick Hamon, CEO of IVCC added: “A future network of GLP certified trials sites across Africa will allow manufacturers of vector control products to generate their own efficacy data for inclusion in their product dossiers submitted to the WHO product evaluation process. This represents a major step forward for vector control product testing, which will be of major importance in delivering the IVCC mission and malaria elimination in the future.”

Six further IVCC collaborating trials sites are now planning their GLP studies and will be submitting their applications for OECD GLP certification through SANAS.

Notes to journalist

IVCC

IVCC is a non-profit public-private partnership, which aims to save lives, protect health, and increase prosperity in areas where disease transmitted by insects is endemic. It brings together the best minds to develop new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions, it accelerates the process from innovation to impact.  IVCC has several novel public health insecticide active ingredients at the point of final development, for delivery in about 2022.  Although primarily targeted at malaria vectors, these insecticides will have application to other NTDs.  IVCC is also currently exploring control of mosquitoes that transmit outdoors and during the day.

The Innovative Vector Control Consortium (IVCC) is delighted to announce that, resulting from a collaboration with BASF and the London School of Hygiene & Tropical Medicine, a new type of Long Lasting Insecticidal Net (LLIN) has received a recommendation for use by the World Health Organization (WHO).

This new LLIN, Interceptor® G2, combines the current pyrethroid class of public health insecticide used in bednets across malaria endemic countries, with a repurposed insecticide from agriculture called Chlorfenapyr.  The successful mixture of these two active ingredients coated on a LLIN represents a major advance in the mission to overcome insecticide resistance.  Chlorfenapyr has a different mode of action from current WHO recommended public health insecticides.

Liverpool based IVCC played an instrumental part in bringing this product to the recommendation stage, supporting and funding the project during the field trials and, as project partner, leading the technical progress of the project through its External Scientific Advisory Committee (ESAC).

Nick Hamon, CEO of IVCC said: “Interceptor® G2 is a major step forward in the battle against mosquito insecticide resistance.  We hope and expect this to be the first of several novel vector control products IVCC will support bringing to market in the coming years to help eradicate malaria”.

“Developing new vector control tools would not be possible without the dedication of our industry partners and the visionary support of our funders.  Without the financial backing of organisations such as the Bill & Melinda Gates Foundation and UKaid, the complex development, testing and evidence gathering exercises needed to support novel vector control products would simply not be possible.  They, along with BASF, deserve immense credit.”

Dave Malone, Technical Manager at IVCC added; “The growing intensity and distribution of resistance to pyrethroids threatens to undermine the great progress that has been made against malaria by the use of LLINs, particularly in sub-Saharan African where 90 per cent of malaria deaths occur.  By combining pyrethroids with a new class of chemistry, these new LLINs have the potential to protect and save many more lives.”

IVCC is delighted to support the inaugural “World Pest Day” launched in Beijing on 6th June 2017.

Initiated by the Chinese Pest Control Association and with the support of the World Health Organization (WHO), the Federation of Asian & Oceania Pest Managements Association (FAOPMA), the National Pest Management Association  in the USA (NPMA) and the Confederation of European Pest Management Associations (CEPA), the aim of the day is to raise awareness of the devastating impact of pests around the world.

Mosquitoes, are just one of many vector borne pests capable of carrying deadly diseases. Today, there are 2.5 billion people in more than 100 countries threatened by diseases such as dengue, yellow fever, chikungunya, schistosomiasis, dysentery and typhoid.

IVCC continues to develop strong ties with China.  In November 2016 Liu Qiyong, Director, WHO Collaborating Centre for Vector Control Surveillance and Management and current IVCC Board member, hosted a visit by IVCC CEO Nick Hamon to China CDC.  There they discussed novel vector control solutions for Aedes mosquitoes due to their widespread insecticide resistance in the region.   IVCC also invited China CDC to visit the Bill & Melinda Gates Foundation office in Beijing to advocate for China’s continued investment in vector control projects.

Researchers at Duke University in the United States and UK based Product Development Partnership IVCC have proposed a new mechanism for stimulating public sector product development to fight malaria and neglected tropical diseases (NTDs). The Vector Expedited Review Voucher (VERV) is based on a similar proposal, called the Priority Review Voucher (PRV) that has been stimulating drug development in NTDs in the United States since it was first introduced in 2007.

“It’s about reducing inefficiency in the regulatory process, and using the gains to fix a market failure in product development to benefit society as a whole,” said David Ridley, a professor at Duke University’s Fuqua School of Business and part of the team proposing the voucher reward for approving new public health insecticides through the U.S. Environmental Protection Agency (EPA).

The team’s findings, “A Voucher System to Speed Regulatory Review Could Promote a New Generation of Insecticides to Fight Vector-Borne Diseases,” are published in the August edition of Health Affairs.

Nick Hamon, CEO of IVCC said: “Insecticides used in bednets and for treating homes have prevented millions of deaths from malaria and other diseases. But while the population of disease-carrying insects resistant to current treatments has grown, no new class of insecticides have been developed specifically for public health in the last 40 years because there is little profit opportunity to innovate in these markets.”

The Vector Expedited Review Voucher proposal would offer the company behind the new product an expedited regulatory review for a second, more profitable product intended to protect crops – as a way to encourage large agrochemical companies to invest in developing less profitable innovative products for public health use.

The VERV proposal is based on the system David Ridley, Jeffrey Moe and Henry Grabowski of Duke University proposed for the U.S. Food and Drug Administration a decade ago to encourage the development of treatments for neglected tropical diseases.

Congress made that proposal law in 2007. The FDA has issued 14 vouchers since that program began. They offer review of a drug in six months rather than the usual 10 months, which can make a huge difference to firms bringing a new product to market. Seven of the vouchers issued so far have been sold, fetching as much as $350 million.

“We brought a creative solution to drug development, and now we want to apply it to public health insecticide development,” Moe said.

Ridley and Moe partnered with Nick Hamon, CEO of the IVCC, a UK based not for profit product development partnership (PDP) that works to prevent the spread of malaria and other NTDs. IVCC is funded by the Bill & Melinda Gates Foundation, UKaid, USAID, Unitaid and The Swiss Agency for Corporation and Development (SDC).

“Medicines are an important tool in fighting these diseases, but they are not the only tool,” said Professor Moe. Whereas 65 percent of research and development funding for malaria was for drugs and vaccines, only 6 percent was for vector control, according to the paper. Similarly, the market for vector control insecticides is significantly less than $1 billion, while agricultural chemicals exceed $47 billion in annual sales. The development of a novel insecticide from discovery through to launch can cost between $100-$250m can take up to twelve years, making a return on investment in vector control almost impossible. Awarding a VERV gives an innovator company an opportunity to generate a financial return on an agricultural product as well as reducing the time to market of critically important products.

The Vector Expedited Review Voucher (VERV) proposal incorporates lessons learned through 10 years of the FDA Priority Review Voucher program, by proposing that ensuring that projects that gain a voucher are truly novel and will go where they’re needed.

“Not a week goes by in which we don’t discuss ways we can make the voucher review program better,” Ridley said.

Ridley, who also works with Duke’s Margolis Center for Health Policy, said he expects to see more of the vector review vouchers to be used by the companies that win them, because the industry is dominated by larger players that are less likely to sell to competitors.

“However, we might be surprised,” he said. “There could be companies we’ve never heard of that receive investor funding and develop products because of the potential value of a VERV. That’s one of the beauties of prizes like this – you don’t pick the winners in advance.”